Biomimetic approaches for targeting tumor-promoting inflammation. (November 2022)

• Record Type: Journal Article
• Authors: Parodi, Alessandro; Kostyushev, Dmitry; Brezgin, Sergey; Kostyusheva, Anastasiya; Borodina, Tatiana; Akasov, Roman; Frolova, Anastasia; Chulanov, Vladimir; Zamyatnin, Andrey A.
• Is Part Of: Seminars in cancer biology. Volume 86(2023)Part 2
• Page Start: 555
• Page End: 567
• Publication Date: 2022-11
• Subjects: Nanomedicine -- Drug delivery -- Biomimicry -- Tumor inflammation; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2022.04.007
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: With the ultimate goal of increasing tumor accumulation of therapeutics, various nanocarriers have been designed to overcome biological barriers encountered at each stage, from drug administration to the cancerous lesion. Stabilizing circulation and functionalization of the targeting surface impart high tumor accumulation properties to nanocarriers. However, various cells can recognize and infiltrate the tumor microenvironment more efficiently than synthetic carriers via overexpression of adhesive ligands, particularly in inflamed stroma of tumors. Thus, a new field of nanomedicine, called biomimicry, has evolved to generate nanoparticles with the same biological characteristics as cells that naturally infiltrate tumors. Revolutionary synthetic processes have been developed to transfer the cell membrane of leukocytes and mesenchymal cells to synthetic carriers. In addition, cells can generate their own "nanocarriers, " known as exosomes, to transport molecular messages to distant sites, while biomimicry of viral and bacterial agents allows high targeting efficiency towards inflammatory immune cells. Alterations in the protein expression in cancer cells caused by inflammation can also be exploited for drug delivery. Finally, new developments in biomimetic drug delivery focus on turning the infiltrating cells into microcarriers that can actively perfuse the tumor and eventually release their therapeutic payload. In this review, we summarize recent developments in biomimetic drug delivery with a particular focus on targeting the tumor inflammatory microenvironment.